about
Oncolytic viruses: finally deliveringRetinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial.Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the ratUltrasound-enhanced drug delivery for cancerMEN1 gene replacement therapy reduces proliferation rates in a mouse model of pituitary adenomas.Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic AdenovirusLong-term physiologically regulated expression of the low-density lipoprotein receptor in vivo using genomic DNA mini-gene constructsConjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo.Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators.Actin-resistant DNAse I Expression From Oncolytic Adenovirus Enadenotucirev Enhances Its Intratumoral Spread and Reduces Tumor Growth.Selective permeabilization of the blood-brain barrier at sites of metastasis.Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1.Adenovirus-derived vectors for prostate cancer gene therapy.Clinical adenoviral gene therapy for prostate cancer.OvAd1, a Novel, Potent, and Selective Chimeric Oncolytic Virus Developed for Ovarian Cancer by 3D-Directed Evolution.Virotherapy--cancer targeted pharmacology.Improved in vitro human tumor models for cancer gene therapy.Macrophages and their interactions with oncolytic viruses.Combining Oncolytic Adenovirus with Radiation-A Paradigm for the Future of Radiosensitization.Group B adenovirus enadenotucirev infects polarised colorectal cancer cells efficiently from the basolateral surface expected to be encountered during intravenous delivery to treat disseminated cancer.Increasing the density of nanomedicines improves their ultrasound-mediated delivery to tumours.Tissue-specific attenuation of oncolytic sindbis virus without compromised genetic stability.Thermoresponsive Polymer Nanoparticles Co-deliver RSV F Trimers with a TLR-7/8 Adjuvant.Under Pressure: Elevated Blood Pressure Enhances Targeting of Tumors by Oncolytic Viruses.Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus.Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses.Making Oncolytic Virotherapy a Clinical Reality: The European Contribution.Evolutionarily conserved primary TNF sequences relate to its primitive functions in cell death induction.Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies.Fluorescence studies of the intra-cellular distribution of zinc bis(thiosemicarbazone) complexes in human cancer cells.In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity.Novel vectors for gene delivery formed by self-assembly of DNA with poly(L-lysine) grafted with hydrophilic polymers.Nanotherapeutics shielded with a pH responsive polymeric layer.Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection.Non-invasive and real-time passive acoustic mapping of ultrasound-mediated drug delivery.Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood.Combining virotherapy and angiotherapy for the treatment of breast cancer.Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies.CTb targeted non-viral cDNA delivery enhances transgene expression in neurons.8th international conference on oncolytic virus therapeutics.
P50
Q26772039-6213AF34-9504-4DE5-8B94-DEF4E64D9DFAQ28306059-DC990209-6DD5-4461-8492-1D43BD14D4DBQ28325177-C68C4A42-310A-4C15-83A1-830ADD9BB3FDQ29035807-56CEDF6F-3B8C-412D-948A-88DE0473AF95Q30558844-AC0E26B6-4C99-4961-BEA9-FBF33D61924BQ33633287-195F7BCB-DFA3-47AC-8A95-960EBE6A905DQ33730675-1AFD0138-DD07-4472-A335-93B7398E5BE0Q35461362-E3835918-1403-4B1D-B889-8E4AE0889AA0Q36323413-915B9313-2AAF-4D63-9D20-2061C8C830C3Q36951268-46A4064D-420C-4462-9C2D-22268DC6C813Q37281601-E130A93F-1D93-41F4-A510-BDBFD6028273Q37446484-B0CEBBE1-F04F-4B7C-BD0D-9E8ABED4918BQ37641338-0CF5A1F5-3556-4970-9A34-4ECBA019F0B5Q37641338-10390C0B-D176-4D2E-94EA-037FFDBC2AA0Q37650343-5F7EB815-97DA-4124-BF44-C3239C319DA5Q37650343-80BFC038-BDCE-4458-BB65-9787768B4D75Q37718560-0247009B-A05D-464C-BEE2-F500EB6C7303Q37971268-45454EB8-839B-4483-87A6-ADCAD7A36217Q38390708-C8EE46D1-3C45-427E-ABEE-B4761C9D32CDQ38545399-2AA1BFC9-4967-4CFC-808C-FACD101AA43DQ38645128-7316E8E5-B5FB-4823-A4FD-01BAB9BF9F60Q38713629-FC2CA79B-120D-4744-A34F-74BD2B6B9E3AQ38874750-32BE4B4D-5199-4BCB-8049-AA31F7BCC5AEQ39020996-708D0EE9-4285-490E-93B3-0A5164BD4A00Q39432685-B4D36EFD-7A94-459E-9012-32A56F71D15CQ39788581-94FEC4DC-5AF4-4910-9283-02F6A874E587Q39949720-EC6020F4-8555-4C7D-B422-C16FE862225FQ40043393-097156AF-5117-4766-AFB2-5A6218E7E9C9Q40088979-49170772-7054-4ECD-AC5B-C30DBC502B5FQ40147449-BA1F0F60-9342-4404-8BA0-ABAA85175FA9Q40152125-6864D294-830D-4634-AA0F-D121B7453324Q40460525-54CCB836-6100-429B-B394-1D8DB0614B5AQ40937108-3680B2C4-B9FE-4110-A632-C2523430CD7EQ41041184-FDA4C161-C2F0-43DB-B59C-11B606DA0DA7Q41248811-CB719F86-ED52-421B-99C5-42EF77200A5FQ41706961-044E6AFF-F577-422C-87C3-0F90C8E7C655Q42201640-7ECABF36-0FBB-4CF2-8F63-A9A854E23E3EQ42236177-5E566D98-8445-4753-8DD7-6510E322962AQ42284431-D79E1D8E-809C-48FD-830F-61D03DFF3B04Q43583253-123B39EC-2029-46A1-9D92-1BEA37B82F48
P50
description
researcher ORCID ID = 0000-0003-3825-0841
@en
wetenschapper
@nl
name
Len Seymour
@ast
Len Seymour
@en
Len Seymour
@es
Len Seymour
@nl
type
label
Len Seymour
@ast
Len Seymour
@en
Len Seymour
@es
Len Seymour
@nl
prefLabel
Len Seymour
@ast
Len Seymour
@en
Len Seymour
@es
Len Seymour
@nl
P106
P31
P496
0000-0003-3825-0841